Abstract Library

#4065 DAREON™-7: A Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NEC) have limited treatment options. DLL3 is highly expressed on NEC and is a promising treatment target. In an ongoing Phase I trial (NCT04429087), BI 764532, a DLL3/CD3 IgG-like T-cell engager (TcE), was tolerable with promising activity in pretreated pts with DLL3-positive (+) tumours, including NEC.

Conference:

Presenting Author: Capdevila J

Authors: Capdevila J, Vandamme T, Niccoli P, Mishima S, Kato K,

Keywords: neuroendocrine carcinoma, delta-like ligand, T-cell engager, Phase I,

#3683 Distinct clinico-pathological features of neuroendocrine liver metastases originating from the pancreas and rectum

Introduction: The treatment response and prognosis still remain poor in the metastatic neuroendocrine neoplasms.

Conference:

Presenting Author: Takahiro T

Authors: Tsuchikawa T, Aya M, Tanaka K, Nakanishi Y, Asano T,

Keywords: Neuroendocrine liver metastasis, pancreas, rectum, clinical characteristics,

#3184 Immune heterogeneity and cascade of changes in subtypes of pancreatic neuroendocrine tumors

Introduction: Previously, we published four molecular subtypes of pancreatic neuroendocrine tumors (PanNETs) - met-like primary (MLP)-1 and -2, intermediate and insulinoma- like with different clinical and molecular characteristics. While immunotherapy trials are on-going in PanNETs, the immune landscape of this disease is largely unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Lawlor R, Ragulan C, Patil Y,

Keywords: pancreatic neuroendocrine tumor, immune microenvironment, viral-mimicry pathway, pancreatic cancer, computational methods, T cells, macrophages, immunotherapy, B cells, complement pathway, interferon signalling, STING pathway, hypoxia, necroptosis, tumor ,

#3092 Mismatch repair protein and PD-1/PD-L1 expression in pancreatic neuroendocrine neoplasm

Introduction: The genetic features of pNENs are currently poorly understood, specifically in regards to DNA repair.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Duan X

Authors: Duan X, Hao S, Zhao M, Mi L, Shi J,

Keywords: PD-1, PD-L1, mismatch repair (MMR) protein, prognosis, pancreatic neuroendocrine neoplasm,

#2121 Phase II Study of Temozolomide Monotherapy in Patients of Neuroendocrine Carcinoma with Resistant to Platinum-Based Chemotherapy

Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ichikawa Y, Kobayashi N, Tokuhisa M, Goto A, Hiroshima Y,

Keywords: Neuroendocrine Carcinoma, Temozolomide,